On a typical Tuesday morning, I see two patients with almost identical PHQ-9 scores of 18—moderately severe depression. The first pays privately. She saw a therapist within a week, chose her antidepressant from a formulary that included newer drugs, and has a follow-up booked for 45 minutes. The second waits six months for NHS talking therapy, gets a default SSRI because of local formulary restrictions, and his 10-minute review slot is already running 20 minutes late. Their depression is the same. Their care is not.

A GP Sees Two Different Depressions in One Day

The morning private patient is a freelance consultant. She can adjust her work schedule to attend weekly therapy sessions. Her private GP prescribes escitalopram after a discussion about side-effect profiles; the cost is covered by her health insurance. She leaves with a plan for a phased return to work and a referral to a psychiatrist if needed—all within the same week.

The afternoon NHS patient works in a warehouse on zero-hours contract. He cannot take time off for appointments without losing wages. His GP—constrained by the local integrated care board (ICB) formulary—starts him on citalopram, the cheapest SSRI. The referral for cognitive behavioural therapy (CBT) goes onto a waiting list where the average wait is 18 weeks. He is told to come back in four weeks, but the next available appointment is six weeks away.

These two patients share a diagnosis but face radically different trajectories. The private patient will likely recover sooner, with fewer side effects, and with support to maintain employment. The NHS patient may drop out of treatment, experience prolonged symptoms, and risk job loss. The difference is not in their biology but in their bank balance.

Wealth buys time, continuity, and medication choice. It buys the ability to recover without financial penalty. This is not a disease gradient but a system one—a two-tier depression pathway built into the structure of UK primary care.

Consider another example: a university administrator with moderate depression who pays for private therapy. She sees a counsellor within days, uses a mix of CBT and mindfulness, and her employer offers flexible hours. Her NHS counterpart—a cleaner on a zero-hours contract—is referred to IAPT, waits 16 weeks for a phone assessment, and is offered a group CBT session that clashes with her shifts. She misses the first session, is discharged, and must be re-referred. By then, her depression has worsened. The private patient recovers in three months; the NHS patient may take a year or more, if she recovers at all. These are not isolated anecdotes but patterns repeated across thousands of GP consultations every week.

How NICE Guidelines Become Two-Tier in Practice

The National Institute for Health and Care Excellence (NICE) recommends stepped care for depression: watchful waiting for mild cases, low-intensity psychological interventions for moderate depression, and high-intensity therapy or medication for severe cases. In theory, this applies equally to all patients. In practice, adherence depends on postcode and income.

Step 1—watchful waiting—works well for patients who can take time off work, exercise, and maintain social routines. For a single parent working two jobs, watchful waiting is a recipe for deterioration. By the time they return to the GP, depression is often severe enough to require medication, but the therapy wait remains unchanged.

Step 2—low-intensity CBT—has a typical NHS wait of two to three months, and sometimes longer in deprived areas. Private patients can access the same therapy within days. They also skip the low-intensity step entirely and go straight to high-intensity therapy or a psychiatrist assessment, which NICE reserves for severe cases but private insurers often cover for moderate depression too.

The result is a system where the same guideline produces different care for different people. A private patient might recover in three months; an NHS patient might wait three months just to start. The guideline is equitable in design but inequitable in delivery.

One could argue that NICE guidelines are intentionally conservative to ensure safety and cost-effectiveness. Yet the cost-effectiveness calculation changes when you account for the long-term consequences of delayed treatment: lost productivity, welfare dependency, and chronicity. A 2023 analysis by the London School of Economics estimated that untreated depression costs the UK economy roughly £30–40 billion annually, a figure that dwarfs the cost of expanding therapy access. The trade-off is not between spending and saving but between spending now and spending more later. NICE's stepped care model, while evidence-based, assumes a level of service capacity that does not exist in many areas. The guideline is not the problem; the under-resourcing is.

Antidepressant Prescribing Patterns Mirror Income

Prescribing data from NHS Digital show that SSRIs remain the most common antidepressants dispensed in deprived areas. In wealthier areas, SNRIs and augmentation strategies—such as adding a second drug or using atypical antipsychotics—are prescribed more frequently. This is partly due to formulary restrictions: many ICBs require GPs to try two SSRIs before requesting a non-formulary drug, a step that takes weeks.

Talking therapy uptake is roughly three times higher in the top income quintile than the bottom, according to a 2023 analysis by the Health Foundation. Even when therapy is available, patients in deprived areas are more likely to miss appointments—DNA (did not attend) rates are consistently higher in lower-income postcodes. This is often framed as lack of motivation, but it reflects practical barriers: transport costs, childcare, inflexible employers.

Polypharmacy and switching rates also differ. Wealthier patients are more likely to have their medication changed promptly if side effects occur. In deprived areas, GPs may be reluctant to switch drugs due to repeat prescribing costs and limited follow-up capacity. The patient ends up on a drug that works less well, or they stop taking it altogether.

Formulary restrictions hit GP discretion hardest. A GP in a deprived practice may want to prescribe mirtazapine for its sleep benefits, but the ICB requires prior approval. That paperwork takes time the GP does not have. The patient gets a less suitable drug, and the cycle of non-response continues.

Consider the case of agomelatine, a newer antidepressant with a favourable side-effect profile but higher cost. In many ICBs, it is restricted to specialist initiation only. A wealthy patient can see a private psychiatrist who prescribes it within a week. An NHS patient's GP must navigate a lengthy approval process, during which the patient may disengage. The result is that newer, potentially better-tolerated drugs are disproportionately available to those who can pay. This is not a matter of clinical superiority—agomelatine is not necessarily more effective than SSRIs—but of choice and tolerability. A patient who has a choice is more likely to adhere to treatment. Adherence improves outcomes, and better outcomes reduce long-term costs. Yet the system prioritises short-term savings over long-term effectiveness.

The Hidden Cost of Chronic Depression: Work and Welfare

Depression is the leading cause of sickness absence in the UK, accounting for roughly 30% of all fit notes issued. The cost to the economy is estimated in the tens of billions annually, but the human cost falls unevenly. Higher-income patients often have access to occupational health services, phased return protocols, and employer flexibility. They can recover without losing their job.

Lower-income patients, by contrast, face a cycle of fit notes, reduced hours, and eventual dismissal. Many end up claiming Employment and Support Allowance (ESA) or Personal Independence Payment (PIP). Data from the Department for Work and Pensions show that mental health conditions are the most common reason for ESA claims, and claimants are disproportionately from the most deprived areas.

Therapy access could reduce benefit spending. A 2022 report by the Centre for Mental Health estimated that expanding talking therapies could save the government roughly £3 for every £1 spent, through reduced benefit claims and increased tax revenue. But the upfront investment required is large, and ICBs face competing demands from cancer, dementia, and diabetes care.

This is a classic cost-shift: the health system saves money by limiting therapy access, but the welfare system and local economies pay more. The GP sees the consequence in every consultation: a patient who has been on the waiting list for months, now unable to work, and sinking deeper into depression.

One counter-argument is that expanding therapy access might not yield the expected savings if the additional patients have complex needs that are not easily resolved by brief CBT. However, even modest effect sizes can be cost-effective when the comparator is no treatment. A 2024 Cochrane review of low-intensity CBT for depression found that it produced small to moderate improvements in symptom scores, with effect sizes comparable to those of antidepressants. The issue is not efficacy but reach. Currently, only about one in six patients with depression in England receives any form of psychological therapy within a year of diagnosis. Increasing that proportion, even modestly, would likely reduce the burden on the welfare system.

Integrated Care Boards and the Inverse Care Law

The inverse care law—that those who need care most are least likely to receive it—applies starkly to depression services. ICBs commission talking therapies through local contracts, and the distribution of providers follows funding patterns. Wealthy areas have more IAPT (Improving Access to Psychological Therapies) providers per capita, shorter waits, and better recovery rates.

The NHS Talking Therapies programme (formerly IAPT) has expanded significantly since its launch in 2008, but expansion has been uneven. A 2024 analysis by the Royal College of Psychiatrists found that recovery rates in the most deprived ICBs were roughly 10 percentage points lower than in the least deprived. Waiting times were twice as long in some areas.

Remote CBT, introduced widely during the pandemic, helped some patients access therapy from home. But it also created a digital divide: patients without reliable internet, private space, or digital literacy were excluded. Data from NHS Digital show that remote therapy completion rates are lower in deprived areas, partly because patients share devices or lack privacy.

Deprived CCGs (now part of ICBs) report longer waits and higher DNA rates, but also higher demand. A GP in a deprived practice might refer ten patients for therapy in a week; a GP in a wealthy practice might refer two. The system is not designed to handle that volume, so waits lengthen, and patients disengage.

A trade-off exists between standardisation and local flexibility. National targets for IAPT recovery rates (currently set at 50%) incentivise services to select patients who are more likely to recover quickly—often those with milder depression and fewer social complexities. This cream-skimming effect disadvantages deprived areas, where patients are more likely to have multiple comorbidities, unstable housing, or financial stress. Some ICBs have tried to adjust targets for deprivation, but these adjustments are not yet widespread. The result is that services in deprived areas are penalised for factors beyond their control, leading to a cycle of underfunding and poor performance.

What a Fair Depression Pathway Would Look Like

A fair system would ring-fence psychological therapy funding according to deprivation indices, so that areas with highest need get the most resources. Some ICBs have begun piloting this—for example, the 'proportionate universalism' approach in Greater Manchester—but it remains the exception.

Same-day GP booking for depression follow-ups would reduce drop-out. Currently, a patient who misses a review appointment may wait weeks for another. A same-day phone slot, even five minutes, could keep them engaged and allow medication adjustment before the patient disengages entirely.

Peer support workers, embedded in GP practices, have shown promise in community settings. They can offer practical advice on benefits, housing, and isolation—things a GP cannot address in a 10-minute slot. The NHS Long Term Plan committed to expanding social prescribing, but implementation is patchy.

Linking welfare advice to depression reviews would address the root cause of many depressive episodes: financial insecurity. A patient who is worried about debt may not respond to CBT until the debt is resolved. Yet GP practices rarely have welfare advisers on site, and referral pathways are unclear.

Another promising approach is collaborative care, where a care manager coordinates between GP, therapist, and psychiatrist, with regular monitoring and stepped treatment adjustments. Trials in the UK, such as the CADET study, have shown that collaborative care improves depression outcomes and is cost-effective compared to usual GP care. Despite this, collaborative care is not widely implemented, largely due to funding silos and workforce shortages. A fair pathway would embed collaborative care in deprived practices, where the need is greatest.

Finally, recovery rates should be measured and published by deprivation decile, so that ICBs are held accountable for equity. Without transparency, the gap will continue to widen unnoticed. Some ICBs have started publishing outcome data by ethnicity and age, but income-based reporting remains rare. A national requirement to report by deprivation would create pressure to address disparities.

The GP's Role in a System That Asks Too Much

A GP cannot correct structural inequality in 10 minutes. But we can flag unmet need, advocate for resources, and push back when formularies restrict evidence-based prescribing. We can ask about work, housing, and debt—not because we can fix them, but because the answers shape treatment.

Depression care is a proxy for social justice. The same PHQ-9 score leads to a different outcome depending on income. That is not a failure of clinical guidelines but of how they are resourced and delivered. We need fewer guidelines and more equitable delivery.

Until the system addresses the underlying divide, the split will widen. Wealth will continue to buy better mental health, and the NHS will continue to do its best with too little. GPs will keep seeing two depressions in one day, and we will keep knowing which patient will recover and which will struggle—before they even speak.

Some might argue that the NHS is a universal service and that the private sector is a safety valve that reduces pressure on the public system. But the evidence suggests that private care does not reduce NHS demand; it creates a two-tier system where those who can afford to opt out reduce the political pressure to improve NHS services. The existence of a private alternative makes it easier for policymakers to tolerate long NHS waits, because the affluent are not affected. This is the paradox of private healthcare in a public system: it undermines the very universality it claims to supplement.

As GPs, we cannot resolve these structural issues alone. But we can bear witness to the disparity, document it in our records, and advocate for change through our professional bodies. The Royal College of GPs and the British Medical Association have both called for increased investment in mental health services, but political will remains insufficient. Until the gap is addressed, the two-tier depression pathway will persist, and the PHQ-9 score will remain a poor predictor of recovery—not because it measures the wrong thing, but because it measures only the patient, not the system.

Disclaimer: This article is for informational purposes only and does not constitute personalised medical advice. Always consult a qualified healthcare professional for individual health concerns.